The global MG diagnosis and treatment market is anticipated to grow significantly at a CAGR of 7.9% during the forecast period. The primary factor which is strengthening the growth of the market is the rise in various rare diseases across the globe. There are around 7,000 rare diseases that affect millions of people which are underserved patient communities across the globe, with only 5% of known rare diseases having one or more approved treatments. Early diagnosis of rare diseases is a challenge owing to multiple factors that include a lack of awareness among primary care physicians, and a lack of adequate screening and diagnostic facilities.
Browse the full report description “Global Myasthenia Gravis (MG) Diagnosis and Treatment Market Size, Share & Trends Analysis Report by Treatment (Medication, Surgery, and Others), by Diagnosis (Edrophonium Tests, Blood Tests, Pulmonary Function Tests, Electrodiagnostic, Imaging, and Others), and by End-Users (Hospitals, Clinics, and Others) Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/myasthenia-gravis-market
Rare diseases are often serious, chronic, and life-threatening conditions. WHO defines a rare disease as often debilitating lifelong disease or disorder with a prevalence of 1 or less, per 1000 population. According to the Ministry of Health family welfare, the Government of India, 300 million people live with rare diseases across the globe, with 72 % of rare diseases being genetic. Out which 70% of those genetic rare diseases start in childhood. These factors significantly grow the global myasthenia diagnosis and treatment market. As Delay in diagnosis or a wrong diagnosis increases the suffering of the patients. There is an immediate need to create awareness amongst the general public, patients & their families, and training doctors for early and accurate diagnosis, standardization of diagnostic modalities, and development of newer diagnostic and therapeutic tools.
Market Coverage
Segment Covered-
Regions Covered-
Competitive Landscape- Alexion Pharmaceutical Inc., Novartis AG, Grifols SA, F. Hoffmann-La Roche, Ltd., and others.
Key questions addressed by the report
oRecovery Timeline
oDeviation from the pre-COVID forecast
oMost affected region/segment
Global Myasthenia Gravis (MG) Diagnosis and Treatment Market– Segmentation
By Treatment
By Diagnosis
By End-Users
Global Myasthenia Gravis (MG) Diagnosis and Treatment Market by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/myasthenia-gravis-market